Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyBlue KC outpatient drug testing Coverage Update | …
    Ask Trek AI about this page
    CurrentBlue KCPolicy POL-PP-303

    Payment Integrity Compliance — Prescription Medication and Illicit Drug Testing in the Outpatient Setting

    Customize your policy alerts

    Sign up for Blue KC Policy POL-PP-303 alerts

    Get alerted when Policy POL-PP-303 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Blue KC's coverage criteria and coding guidance for outpatient clinical toxicology (presumptive and definitive drug testing) for prescription medication and illicit drug testing; applies to professional and facility providers across commercial and Medicare Advantage lines of business.

    Policy Summary
    PayerBlue KC
    PolicyPrescription Medication and Illicit Drug Testing in the Outpatient Setting
    Policy CodePolicy POL-PP-303
    Change TypeNo material change
    Effective DateJul 1, 2025
    Next Review DateJul 1, 2026
    Key ActionPresumptive urine drug screening may be reimbursed for chronic non-cancer pain management and other specified clinical situations with defined frequency limits; definitive testing reimbursed when results conflict with clinical presentation or specific confirmation is needed.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    up to 4/yrmax presumptive monitoring (high risk)
    1-2/wkpresumptive testing (0-90 days abstinence)
    ≤3/modefinitive test limit (31-90 days)
    excludedproprietary tests
    not coveredspecimen validity testing

    Outpatient Drug Testing Coverage Criteria

    Outpatient drug testing coverage criteria

    Covered when ALL of the following conditions and limits are met:

    Presumptive urine drug screening or definitive drug testing is eligible for reimbursement only under the clinical situations and frequency limits described below.

    Eligible clinical indications (ONE or more):

    • Assessment or monitoring of an individual treated for chronic non-cancer pain when clinical evaluation suggests use of non-prescribed medications or illegal substances, including: baseline assessment prior to initiating chronic opioid therapy, routine monitoring to verify compliance or detect undisclosed drug abuse (random testing intervals and drugs selected based on documented history/condition/treatment), and risk-based monitoring (low risk: up to 1/year; moderate risk: up to 2/year; high risk: up to 4/year).
    • Testing at the time of visit for individuals with aberrant behavior (e.g., lost prescriptions, multiple early refill requests, opioids from multiple providers, unauthorized dose escalation, apparent intoxication).
    • Pregnant individuals at high risk for substance use when suspicion is documented (based on screening questions or PDMP data).
    • Newborns when there is a history of maternal substance abuse or agitated/altered mental status in the birthing parent.
    • Organ transplant candidates with a history of substance abuse to demonstrate abstinence prior to transplant.
    • Individuals with suspected or diagnosed mental illness (e.g., anxiety disorders, schizophrenia, major depressive disorder, mood disorders, suicidal ideation, substance use disorder).
    • Individuals with attention-deficit hyperactivity and disruptive behavior disorders.
    • Cancer patients receiving opioid pain medication.
    • Individuals with epilepsy.
    • When substance abuse is in the differential diagnosis of the presenting condition.

    Substance use disorder / treatment monitoring (ONE of):

    • For patients with 0 to 30 consecutive days of abstinence: random definitive drug testing at a frequency not to exceed 1 per week.
    • For patients with 31 to 90 consecutive days of abstinence: random definitive drug testing at a frequency of 1 to 3 per month; no more than 3 definitive drug tests in one month will be allowed.
    • For patients with greater than 90 consecutive days of abstinence: definitive drug testing at a frequency of 1 to 3 every three months; no more than 3 definitive drug tests in a 3-month period will be allowed.
    • For patients in substance use treatment, random qualitative presumptive testing frequency: 0–90 days abstinence: 1–2 per week; >90 days abstinence: 1–3 per month (after baseline at initial evaluation).

    Definitive testing clinical justifications (ONE or more):

    • A presumptive drug screen result is inconsistent with the patient’s history, clinical presentation, or reported medications (e.g., negative for prescribed medication or positive for unprescribed/illegal drugs).
    • A presumptive test does not exist or does not adequately detect the specific drug or metabolite of interest (including certain synthetics/analogs or designer drugs).
    • A definitive concentration is needed to guide clinical management or to definitively identify specific drugs within a large drug family.
    • Monitoring individuals on opioid therapy when accurate and reliable results are necessary for treatment decisions.

    Limits and non-reimbursable items:

    • Specimen validity testing (e.g., urine specific gravity, urine creatinine, pH, urine oxidant level, genetic identity testing) is not reimbursed.
    • Laboratory-based definitive drug testing requested for panels larger than seven drug classes may not be reimbursed.
    • Confirmatory/definitive or presumptive testing using certain proprietary tests (e.g., CareView360) may not be reimbursed.

    Exclusions (not covered under this policy):

    • State- or federally-mandated/forensic testing and testing required for legal proceedings.
    • Employment-related testing.
    • Testing performed as part of routine physical examinations, urgent/emergency care, or routine behavioral health assessments.

    All testing and frequencies must be documented in the medical record, including baseline evaluation and rationale for continued monitoring as applicable.

    CPT/HCPCS and Proprietary Codes

    Presumptive CPT CodesCPTCovered
    80305Presumptive drug test(s), any number of drug classes read by direct optical observation; includes sample validation when performed
    80306Presumptive drug test(s) read by instrument assisted direct optical observation; includes sample validation when performed
    80307Presumptive/initial drug test(s) by instrument chemistry analyzers or chromatography/mass spectrometry; includes sample validation when performed
    Definitive HCPCS/CPT Codes (1-7 to 22+ classes)mixedCovered
    G0480Definitive drug test(s), 1-7 drug classes, qualitative or quantitative, includes specimen validity testing
    G0481Definitive drug test(s), 8-14 drug classes, qualitative or quantitative, includes specimen validity testing
    G0482Definitive drug test(s), 15-21 drug classes, qualitative or quantitative, includes specimen validity testing
    G0483Definitive drug test(s), analogous description for higher class counts
    G0659Definitive drug test(s), 22 or more drug classes, includes specimen validity testing
    Billing rules (applies to presumptive and definitive codes)mixed
    No codes listed
    Proprietary / LDT Codesmixed
    0007UProprietary presumptive with definitive confirmation, includes DNA authentication (ToxProtect)
    0011UPrescription drug monitoring, oral fluid LC-MS/MS (Cordant CORE™)
    0051UUrine 31 drug panel LC-MS/MS (UCompliDx)
    0054UCapillary blood definitive tandem MS quantitative report (AssuranceRx Micro Serum)
    0079UComparative DNA analysis for specimen identity verification (ToxLok™)
    0082UDefinitive 90+ drug panel plus presumptive immunoassay (NextGen Precision™ Testing)
    0093UUrine LC-MS/MS 65-drug panel (ComplyRX)
    0227UPresumptive assay, 30+ drugs, urine LC-MS/MS
    0328UDefinitive 120+ drug panel, urine quantitative LC-MS/MS (CareView360)
    Definitive panel size reimbursement cap — inv-04
    Policy thresholdDefinitive (confirmatory) laboratory-based drug testing requested for panels larger than seven drug classes may not be reimbursed.
    ScopeApplies to laboratory-based definitive qualitative or quantitative drug testing panels requested in the outpatient setting.
    Related codingG0480 covers 1-7 drug classes; requests exceeding this panel size are subject to non-reimbursement per policy.
    Use case impactProviders ordering broad-panel definitive tests should limit panels to 7 drug classes or provide justification in the medical record for medical necessity.
    Proprietary test reimbursement — inv-05
    Proprietary tests excluded

    Provider Billing and Action Requirements

    Prior Authorization

    Follow baseline and risk‑based monitoring, document frequency and clinical indication

    Presumptive urine drug screening may be reimbursed for baseline assessment prior to initiating chronic opioid therapy and for risk‑based routine monitoring of individuals on chronic opioid therapy (low risk: up to 1/year; moderate risk: up to 2/year; high risk: up to 4/year). Definitive (confirmatory) testing may be reimbursed when presumptive results conflict with clinical presentation, when presumptive tests do not detect the specific drug/metabolite, when definitive concentrations are needed to guide management, and for monitoring individuals in substance use treatment per the frequency limits by abstinence duration (see policy for exact limits). All testing and monitoring frequency must be documented in the patient's medical record.

    • Substance use treatment monitoring – definitive testing frequency: 0–30 days abstinence: ≤1/week; 31–90 days: 1–3/month (no more than 3 in one month); >90 days: 1–3 every three months (no more than 3 in a 3‑month period).
    • Presumptive monitoring for substance use treatment – 0–90 days abstinence: 1–2 random qualitative tests/week; >90 days: 1–3 random qualitative tests/month.
    • Presumptive testing reimbursed for baseline evaluation, verification of treatment compliance, testing at time of visit for aberrant behavior, high‑risk pregnancy, newborns with maternal substance use history, transplant candidates, mental illness, ADHD, cancer patients on opioids, and individuals with epilepsy.

    Defined Terms

    Forensic testing — inv-08
    DefinitionForensic drug testing: testing used for legal proceedings that requires secondary confirmatory testing.
    Policy statusThis outpatient clinical toxicology policy does not address forensic testing; forensic testing is excluded from the coverage criteria.
    Confirmatory requirementFor legal/forensic purposes, secondary confirmatory testing is required to meet evidentiary standards.
    Therapeutic drug monitoring (TDM) — inv-09
    DefinitionTherapeutic drug monitoring (TDM): sampling of plasma or serum drug levels to determine optimal drug dosing.
    Policy scopeTDM is not addressed by this outpatient clinical toxicology policy and is excluded from its coverage criteria.
    Policy Summary
    PayerBlue KC
    PolicyPrescription Medication and Illicit Drug Testing in the Outpatient Setting
    Policy CodePolicy POL-PP-303
    Change TypeNo material change
    Effective DateJul 1, 2025
    Next Review DateJul 1, 2026
    Key ActionPresumptive urine drug screening may be reimbursed for chronic non-cancer pain management and other specified clinical situations with defined frequency limits; definitive testing reimbursed when results conflict with clinical presentation or specific confirmation is needed.
    SourceLink
    On This Page
    Outpatient Drug Testing Coverage CriteriaCPT/HCPCS and Proprietary CodesProvider Billing and Action RequirementsDefined Terms
    Confirmatory or presumptive testing using certain proprietary tests (example: CareView360, NextGen Precision™ Testing, ToxLok™, ComplyRX) may not be reimbursed.
    Examples from code list0328U (CareView360), 0082U (NextGen Precision™), 0093U (ComplyRX), 0079U/ToxLok™ referenced as proprietary tests in the policy.
    Coverage implicationWhen a proprietary/LDT assay is submitted for presumptive or definitive testing, claim denial or non-reimbursement may occur per policy guidance.
    Provider actionUse non-proprietary, standard definitive testing methods (e.g., LC-MS/MS with appropriate CPT/HCPCS codes) when possible or document medical necessity if using proprietary assays.
    Denial Risk

    Do not bill Blue KC for mandated, employment, routine physical, urgent/emergency, or routine behavioral health testing

    This policy excludes testing that is state/federally regulated or legally mandated (including court‑ordered or forensic examinations), employment‑related testing (e.g., commercial driver licensing or job‑related screening), testing as a component of routine physical/medical examinations, testing performed as part of urgent/emergency care, and routine behavioral health assessment testing.

    • State, federally regulated, and legally mandated drug testing (forensic/court‑ordered) is excluded.
    • Employment or job‑related testing (including commercial driver licensing) is excluded.
    • Testing performed as part of routine physicals, urgent/emergency care, or routine behavioral health assessments is excluded.
    Typical specimensTDM involves plasma or serum samples rather than urine, per definition and policy scope.
    Specimen validity testing — inv-10
    Included specimen validity testsExamples: urine creatinine, urine specific gravity, urine pH, urine oxidant level, and genetic identity/DNA-based specimen verification (e.g., comparative SNP analysis).
    Reimbursement statusSpecimen validity testing (including creatinine, pH, oxidant levels, and genetic identity testing) may not be reimbursed under this policy.
    PurposeThese tests are used to assess specimen integrity and identity prior to or alongside drug testing.
    Coding examplesGenetic identity/verification tests referenced in proprietary code descriptions (e.g., ToxLok™, NextGen Precision™) are specifically noted in the policy as specimen validity methods.